ABT241011C130000
- 0.09
- 0.000.00%
Abbott Laboratories Newsroom
We Think Abbott Laboratories (NYSE:ABT) Can Manage Its Debt With Ease
Abbott Started at Outperform by Oppenheimer, Diversified Portfolio Cited
Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth
A Look Into Abbott Laboratories Inc's Price Over Earnings
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
RBC Capital Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $130
Express News | Oppenheimer Initiates Coverage On Abbott Laboratories With Outperform Rating, Announces Price Target of $130
Oppenheimer Initiates Abbott Laboratories(ABT.US) With Buy Rating, Announces Target Price $130
Abbott Laboratories Analyst Ratings
Express News | Abbott : RBC Raises Target Price to $130 From $125
How Is The Market Feeling About Abbott Laboratories?
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $133 From $126
Abbott Laboratories (NYSE:ABT) Is Favoured by Institutional Owners Who Hold 77% of the Company
Buy Rating Affirmed for Abbott Laboratories Amid Strong Performance and Favorable Market Trends
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $131
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Altimmune (ALT) and Steris (STE)
WHO Approves First Mpox Diagnostic Test for Emergency Use
Wells Fargo's 'Core' Stocks: GOOGL, HD, KO, and More
Abbott Laboratories Insiders Sold US$7.7m Of Shares Suggesting Hesitancy
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $130